Key points are not available for this paper at this time.
// Qing Zhang 1, * , Haiyu Wang 1, * , Huizhong Li 1 , Jinjing Xu 1 , Kang Tian 1 , Jie Yang 1 , Zheng Lu 1 , Junnian Zheng 1, 2 1 Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, 221002, China 2 Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical College, Xuzhou, Jiangsu, 221002, China * These authors contributed equally to this work Correspondence to: Junnian Zheng, email: jnzheng@xzmc.edu.cn Keywords: chimeric antigen receptor, T cell, tissue factor, lung cancer, melanoma Received: June 17, 2016 Accepted: December 05, 2016 Published: December 30, 2016 ABSTRACT Chimeric antigen receptor (CAR)-modified T cell (CAR T) is a promising therapeutic option for patients with cancer. Such an approach requires the identification of tumor-specific antigen targets that are expressed in solid tumors. We developed a new third-generation CAR directed against tissue factor (TF), a surface molecule overexpressed in some types of lung cancer, melanoma and other cancers. First, we demonstrated by immunohistochemistry that TF was overexpressed in squamous cell carcinoma and adenocarcinoma of non-small cell lung cancer (NSCLC) and melanoma using a human tissue microarray. In the presence of TF-positive cancer cells, the CAR-modified T cells (TF-CAR T) were highly activated and showed specific cytotoxicity to TF-positive cancer cells in vitro . In established s.c. xenograft and lung metastasis models, TF-CAR T cells could significantly suppress the growth of s.c. xenograft and metastasis of TF-positive cancer cells. Additionally, the safety evaluation of TF-CAR T cells in vivo showed that the treatment did not cause obvious toxicity in mice. Taken together, these findings indicate that TF-CAR T cells might be a novel potential therapeutic agent for the treatment of patients with TF-positive cancers.
Zhang et al. (Fri,) studied this question.